Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 17, 2022, titled "Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single‐Dose Pre‐Filled Syringe".